Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Division of Gastroenterology and Hepatology, University of colorado Anschutz Medical Campus, Aurora, CO.
Ann Surg. 2023 May 1;277(5):e1072-e1080. doi: 10.1097/SLA.0000000000005274. Epub 2023 Apr 6.
We evaluated a protocolized endoscopic necrosectomy approach with a lumen-apposing metal stent (LAMS) in patients with large symptomatic walled-off pancreatic necrosis (WON) comprising significant necrotic content, with or without infection.
Randomized trials have shown similar efficacy of endoscopic treatment compared with surgery for infected WON.
We conducted a regulatory, prospective, multicenter single-arm clinical trial examining the efficacy and safety of endoscopic ultrasound -guided LAMS with protocolized necrosectomy to treat symptomatic WON ≥6 cm in diameter with >30% solid necrosis. After LAMS placement, protocolized WON assessment was conducted and endoscopic necrosectomy was performed for insufficient WON size reduction and persistent symptoms. Patients with radiographic WON resolution to ≤ 3 cm and/or 60-day LAMS indwell had LAMS removal, then 6-month follow-up. Primary endpoints were probability of radiographic resolution by 60 days and procedure-related serious adverse events.
Forty consecutive patients were enrolled September 2018 to March 2020, of whom 27 (67.5%) were inpatients and 19 (47.5%) had clinical evidence of infection at their index procedure. Mean WON size was 15.0 ± 5.6 cm with mean 53.2% ± 16.7% solid necrosis. Radiographic WON resolution was seen in 97.5% (95% CI, 86.8%, 99.9%) by 60 days, without recurrence in 34 patients with 6-month follow-up data. Mean time to radiographic WON resolution was 34.1 ± 16.8 days. Serious adverse events occurred in 3 patients (7.5%), including sepsis, vancomycin-resistant enterococcal bacteremia and shock, and upper gastrointestinal bleeding. There were no procedure-related deaths.
Endoscopic ultrasound-guided drainage with protocolized endoscopic necrosectomy to treat large symptomatic or infected walled-off necrotic pancreatic collections was highly effective and safe. Clinicaltrials.-gov no: NCT03525808.
我们评估了一种内镜下清创术联合使用腔内置管金属支架(LAMS)治疗伴有大量症状性包裹性坏死胰腺脓肿(WON)的方案,这些脓肿包含大量坏死组织,无论是否合并感染。
随机试验表明,内镜治疗与手术治疗感染性 WON 的疗效相当。
我们进行了一项监管部门、前瞻性、多中心、单臂临床试验,研究了内镜超声引导下 LAMS 联合方案性清创术治疗直径≥6cm 且>30%为实性坏死的症状性 WON 的疗效和安全性。LAMS 放置后,对 WON 进行方案性评估,如果 WON 缩小不充分且持续存在症状,则进行内镜下清创术。对于影像学上 WON 缩小至≤3cm 和/或 60 天内留置 LAMS 的患者,取出 LAMS,然后进行 6 个月随访。主要终点为 60 天内影像学缓解率和与操作相关的严重不良事件。
2018 年 9 月至 2020 年 3 月期间,连续纳入 40 例患者,其中 27 例(67.5%)为住院患者,19 例(47.5%)在指数操作时有临床感染证据。WON 的平均大小为 15.0±5.6cm,平均 53.2%±16.7%为实性坏死。97.5%(95%可信区间,86.8%,99.9%)的患者在 60 天内影像学上得到缓解,34 例有 6 个月随访数据的患者无复发。影像学上 WON 缓解的平均时间为 34.1±16.8 天。3 例患者(7.5%)发生严重不良事件,包括脓毒症、万古霉素耐药肠球菌菌血症和休克以及上消化道出血。无与操作相关的死亡。
内镜超声引导引流联合方案性内镜下清创术治疗大的症状性或感染性包裹性坏死胰腺脓肿是高效且安全的。临床试验.gov 注册号:NCT03525808。